July 26, 2018

CURRICULUM VITAE

Bartolome Moya Canellas, Ph.D.

Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida. E-mail: bmoya@cop.ufl.edu

ACADEMIC POSITIONS

Since May 2018

03/2016 to 05/2018

Assistant Professor, Center for Pharmacometrics & Systems Pharmacology. Department of Pharmaceutics, College of Pharmacy, University of Florida

Sr. Postdoctoral Fellow, Center for Pharmacometrics & Systems Pharmacology. Department of Pharmaceutics, College of Pharmacy, University of Florida

01/2013 to 12/2015 Senior Research Fellow, Hospital Universitario Son Espases, IdISBa Research Institute of Health Sciences, Univ. of the Balearic Islands, Palma de Mallorca, Spain

09/2010 to 06/2015 Assistant Professor, Department of Biology and Biochemistry, and Department of Fundamental Biology and Health Sciences, UIB University of the Balearic Islands, Palma de Mallorca, Spain

01/2010 to 12/2012 Postdoctoral Fellow (Grant-supported) in Clinical and Molecular Microbiology, Hospital Universitario Son Dureta, IUNICS Research Institute of Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain. (Advisor: Dr. Antonio Oliver Palomo)

EDUCATION

01/2009 to 03/2009 Visiting scientist with Dr. Juan A. Ayala, Madrid, Spain: HPLC muropeptide composition analysis in different characterized β-lactam resistant mutants of Pseudomonas aeruginosa. CBM Centro de Biologia Molecular Severo Ochoa.

07/2005 to 12/2009 Ph.D. on “Hyperproduction of AmpC Chromosomal Cephalosporinase in Pseudomonas aeruginosa: Effect on Fitness and Characterization of New β-lactam Resistance Mechanisms”. Hospital Universitari Son Dureta, IUNICS Research Institute of Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain. (Advisor: Dr. Antonio Oliver Palomo)

06/2008 Postgraduate Educational Course of the European Society for Clinical Microbiolgy and Infectious Diseases (ESCMID). 7th Workshop Javier Benedi. “Mechanisms of antimicrobial resistance. A practical approach”. Palma de Mallorca, Spain

09/2006 to 06/2008 MSc in Advanced Microbiology at the Universitat de les Illes Balears, Palma de Mallorca, Spain

01/2007 to 04/2007 4-month internship at the CNB Centro Nacional de Biotecnologia, Madrid, Spain (Advisor: Dr. Jesus Blazquez): Pseudomonas aeruginosa transposon mutant library screening and RNA microarray analysis.

10/2000 to 06/2005 BSc in Biology, UIB Universitat de les Illes Balears, Palma de Mallorca, Spain. Focus: Human and Bacterial Genetics, Clinical and Food Biochemistry, Genetic engineering, Biotechnology and Microbiology. Minor: Food Microbiology and Biotechnology.

ADDITIONAL PROFESSIONAL EXPERIENCE

08/2012 to 12/2015 Normalized protocol for the detection of Noroviruses from water sources from Central and South America using a novel multiplex RT-PCR assay. (Advisor: Dr. Antonio Domenech)

09/2007 to 11/2007 Core organization team, ESCMID 43rd International Symposium Bacterial Adaptation Mechanisms: Biofilms, Hypermutability and Antibiotic Resistance (BAMBHAR), Palma de Mallorca, Spain

2 | P a g e

06/2005 to 04/2007 Surveillance study: Molecular characterization of ESBL-producer E. coli and K. pneumoniae clinical isolates. Coordination and shipment to the National reference center Instituto de Salud Carlos III. Madrid, Spain

06/2001 to 06/2003 Volunteer service, cleaning and water quality determination from Natural Park s’Albufera, Mallorca, Spain

TEACHING

Course Title Role Contact hours

PHA 6133 Translational Clinical Pharmacology. Concepts and Principles of PKPD, In vitro (IVIVC) animal human scaling, Basic Modeling Methods and Study Design, Empiric and Mechanistic Models for Translational Analyses, Population Modeling Methods & Software, and Achieving Patient Target Goals Precisely Translational Drug Development in Action.

Teaching Assistant

2017

11227 Advanced Genetic Techniques. Master's degree. Applied Biotechnology (MBTA). Master's degree. Biomedical Research (MIBM). Train competent researchers in the field of Biomedicine research, with a solid scientific, advanced, multidisciplinary and integrative knowledge of Biochemistry, Molecular Biology and Cell Biology of Health and Disease. UIB University of the Balearic Islands.

Course coordinator and Lecturer

60 h – 20h/yr. from 2012 to 2015

21533

Genetic Engineering. Degree in Biochemistry (BIQ). Molecular genetics. Study of techniques of the modification of the genetic bases. UIB University of the Balearic Islands.

Course coordinator and Lecturer

96 h – 24 h/yr. from 2010 to 2015

20107

Basic Laboratory Operations. Degree in Biology (BIO). Basic training to work in a laboratory: security, organization and compartmentalization of a laboratory, knowledge and management of equipment and organisms. UIB University of the Balearic Islands.

Course coordinator and Lecturer

168 h – 42 h/yr. from 2010 to 2015

20130

Physiology and Genetics of Plant-Microorganism Interactions. Degree in Biology (BIO). Advanced Molecular techniques to describe the symbiotic plant-microorganism process. UIB University of the Balearic Islands.

Course coordinator and Lecturer

90 h – 30 h/yr. from 2012 to 2015

21534 Human Genetics Degree in Biochemistry (BIQ). Human Molecular genetics. Disease Genetic Biomarkers and insights into genetic diagnosis and therapy. UIB University of the Balearic Islands.

Lecturer 8 h in 2013 & 2014

Workshop 8th and 9th Workshop "Professor V. J. Benedi" Mechanisms of Antimicrobial Resistance – a Practical Approach, ESCMID Postgraduate Technical Workshop.

Workshop organizer, coordinator and Lecturer

70 h – 35 h/yr. 2012 & 2013

Workshop Molecular tools to design and improve your research plan. New Molecular approaches in Genomics, Transcriptomics & Proteomics to enhance research. Critical thinking & research plan development.

Workshop coordinator and Lecturer

4.5 h in 2014

Workshop Proteomics – from bench to bedside. A conceptual and practical approach on how to design new

Workshop organizer,

10 h in 2013

3 | P a g e

proteomic approaches for the diagnostic of infectious diseases.

coordinator and Lecturer

Advising / mentoring: Co-supervisor of 8 PhD students (5 completed).

Training and supervising 14 technicians or intern students (formal) Mentoring two award-winning MSc students Mentoring 8 research intern students (BSc, MSc, PharmD level)

Training 3 technicians and 5 visiting scientists

Leadership & Service: UF College of Pharmacy Search Committee (since 7/2018) Editorial Board Member of Frontiers in Microbiology since 06/2018 Scientific Advisor to Editors of Journal of Pharmaceutical Sciences since 4/2018 Reviewer for over 10 journals since 2009

Communication: Responsible for advertising two international conferences via electronic media, fax and print media; responsible for PowerPoint presentations (up to 20 in parallel)

Languages: Catalan (native), Spanish (native), English (advanced)

Report writing: Primary author of 4 full industry NCE development reports and preparation of presentations for Industry SOP writing for regulatory, reporting and surveillance (2 protocols) and outbreak study reports (14 studies; 6 years experience)

AWARDS

2015 Best Research Paper Postdoctoral Category. IdISPa HUSE

2014

2013

2013

Excellence in Teaching Award - University of the Balearic Islands UIB (96.7 out of 100)

Excellence in Teaching Award - University of the Balearic Islands UIB (95.9 out of 100)

Best Research Paper Postdoctoral Category. IdISPa HUSE

2010 Best Research Paper Postdoctoral Category. IdISPa HUSE

2009 Best Research Paper Corresponding Author Category HUSD IUNICS

2009 Best Research Paper PhD student Category. HUSD IUNICS

2008 Best Research Paper Scholar Category. HUSD IUNICS

2008 Best Short communication award 48th ICAAC/IDSA annual meeting. Washington DC.

2007 Best Research Paper Scholar Category. HUSD IUNICS

2006 Best Research Paper Scholar Category. HUSD IUNICS

2006 Journal Highlights Volume 1, Number 6, 2006 / Microbe. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cepahlosporinase conferring high-level ß-lactam resistance involves three AmpD homologues. AAC 2006; 50:1780-7.

4 | P a g e

EXECUTIVE SUMMARY

Funding Total (since 2005)

Active Under review

All 13 awarded grants $9.7m $8.5m $6m

Peer-reviewed grants (NIH) $8.5m $8.5m $6m

Grants as Principal Investigator (PI) or PD/PI $0.12m $0.1m $0.1m

Peer-reviewed grants as Co-I $5m $5m 6m

Publication Last 3 yr (since 2015)

Last 5 yr (since 2013)

Last 10 yr (since 2008)

Total (since 2005)

All papers 9 15 31 34

Peer-reviewed papers & book chapters 8 14 30 33 a

Original research papers 53 69 111 120

Review papers 1 1 1 1

h-index 20 23

i10-index b 26 28

Citations c 1,254 1,700

a: 97% of papers in top-quartile (Q1) journals. Including PLoS PATHOGENS

(ISSN: 1553-7366; Top 10 microbiology Journals, IF: 9.89). b: Papers with at least 10 citations. c: ISI Web of Knowledge, Scopus, Google Scholar, and Publish or Perish. Full courses taught: 1 (Advanced Genetic Techniques, 6 credit hours)

Full workshops taught: 2 since 2013

Workshops lectures: 4 since 2013

Oral presentations: 36 since 2006 including 6 Invited international podium presentations since 2010

Conference abstracts accepted: 24 since 2008

Summary of awards: 12 young investigator / excellence in teaching awards since 2006

5 | P a g e

GRANT APPLICATIONS

GRANT APPLICATIONS – UNDER REVIEW

Drusano GL (PI), Bulitta JB (Co-I), Louie A (Co-I), Moya B (Co-I), Brown AN (Co-I), Neely M (Co-I), Pucci MJ (Co-I), Hecker EA (Co-I) Developing efficacious combination dosing strategies for a new polymyxin analogue to combat multidrug-resistant superbugs in VABP National Institutes of Health, NIH / NIAID (scored), RFA-AI-17-026 Role: Co-I 12/1/2018 – 11/30/2023, $5,548k

ONGOING PROJECTS

1. Bulitta JB (PI), Schweizer HP (Co-I), Louie A (Co-I), Moya B (Co-I), Drusano GL (Co-I), Basso KB (Co-I), Lee RE (Co-I), Copik A (Co-I), Bonomo R (Co-I), Balasubramanian V (Co-I). Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding. National Institutes of Health, NIH / NIAID, 1R01 AI136803-01 Role: Co-I 3/01/2018 – 2/28/2023, $5,972k (final funded amount and dates pending) 2. Bulitta JB (PI), Louie A (Co-I), Boyce JD (Co-I), Bonomo R (Co-I), Drusano GL (Co-I) Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii National Institutes of Health, NIH / NIAID, 1R01AI130185-01, Role: Named Scientist 12/01/2017 – 11/30/2022, $3,527k 3. Bulitta JB (PI), Basso KB (Co-I), Garrett TJ (Co-I), Louie A (Co-I) Combating resistant Gram-negative bacterial superbugs via omics techniques Role: Named Key Personnel DRPD-ROF2017, University of Florida strategic seed funding, 06/2017 – 05/2019, $95k. 4. Bulitta JB (PI), Louie A (Co-I), Jourjy J (Co-I) Characterizing receptor binding of β-lactam antibiotics to combat resistant ‘superbugs’ Role: Named Key Personnel COP PROSPER 2017, College of Pharmacy, UF, 01/2017 – 12/2017, $36k.

Based on these ongoing projects and my extensive track record in molecular microbiology and proteomics, especially with Pseudomonas aeruginosa, I will substantially contribute to and co-lead two future R01 grant submissions (#1 on P. aeruginosa and #2 on Klebsiella pneumoniae) in the next 12 months. COMPLETED PROJECTS 1. Bulitta JB (PI), Shin BS (Co-PI), Kim TH (Co-I), Moya B (Co-I), Jiao Y (Co-I) Supporting the rational development of a generic formulation by pharmacokinetic data analyses and simulations. Role: Co-I International pharmaceutical industry, 03/2017 – 05/2017, $13k.

2. Bulitta JB (PI), Shin BS (Co-PI), Kim TH (Co-I), Moya B (Co-I), Jiao Y (Co-I) Pharmacokinetic optimization of a new platelet aggregation inhibitor. Role: Co-I International pharmaceutical industry, 03/2017 – 05/2017, $9k. 3. Oliver A (PI), Juan C (Co-I)

6 | P a g e

Genetic markers of resistance, virulence, adaptability, epidemicity and mortality in infections with P. aeruginosa. Role: Senior research coordinator FIS PI12/00103 (Spanish NHS) 01/01/2012 – 12/01/2015, $112k. 4. Oliver A (PI) Moya B (Co-PI) Determination of the PBP binding affinities and killing kinetics of WCK NCEs and comparator drugs in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Role: Co-PI International pharmaceutical industry 01/01/2013 – 12/01/2015, $75k. 5. Oliver A (PI), Maria D. Macia (Co-I), Rojo-Molinero E (Co-I), Moya B (Co-I) Sequential treatment with inhaled antibiotics: therapeutic efficacy and dynamics of resistant and hyper-susceptible populations in Pseudomonas aeruginosa Biofilms; CATINVITRO. Role: Co-I International pharmaceutical industry 06/01/2013 – 12/01/2014, $55k. 6. Oliver A (PI), Moya B (Co-PI) Determination of PBP binding affinities of WCK NCEs and comparator drugs in PAO1 Role: Co-PI International pharmaceutical industry 01/01/2011 – 12/01/2013, $35k. 7. Moya B (PI) Role of PBPs (penicillin binding proteins) in the beta-lactam resistance of Pseudomonas aeruginosa: implications for assessment and development of new antimicrobials. Role: PI Pilot Project 01/01/2011 – 12/01/2012, $6.15k. 8. Oliver A (PI), Moya B (Co-I), Juan C (Co-I) Beta-lactam resistance in Pseudomonas aeruginosa: role of PBP4 and regulation system CreBC. Role: Co-I FIS PS09/00033 (Spanish NHS) 01/01/2009 – 12/01/2012 $232k. 9. Oliver A (PI), Moya B (Co-I), Juan C (Co-I), Zamorano L (Co-I) Evaluation and development of new antimicrobials (CXA-101, CXA-201): Assessment of activity in clinical collections and dynamic strains and development of resistance in vitro and in vivo models, mechanism of action, mechanisms. Role: Co-I International pharmaceutical industry 01/01/2008 – 12/01/2015, $134k. 10. Pena C (PI), Oliver A (Co-I) Molecular epidemiology and clinical bacteremia of Pseudomonas aeruginosa resistant to carbapenems: impact of resistance on mortality. Role: Part-time Postdoctoral research fellow FIS PI08/0802 (Spanish NHS) 01/01/2009 – 12/01/2011 $64k.

11. Oliver A (PI), Moya B (Co-I) Molecular basis of resistance to beta-lactams in Pseudomonas aeruginosa. Role: Co-I Local Government Agency 01/01/2007 – 01/01/2008, $35k.

12. Oliver A (PI) Beta-lactam resistance in Pseudomonas aeruginosa: molecular basis of derepression of chromosomal AmpC cephalosporinase. Role: Predoctoral Fellow SAF 2006-08154 (Spanish Research Council) 01/01/2007 – 12/01/2009, $123k.

7 | P a g e

13. Oliver A (PI) Genetic bases of the dispersion in Spain of extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae. Role: Analysis Coordination and shipment of Isolates of interest FIS PI04/0339 01/01/2005 – 12/01/2007, $176k.

SUMMARY OF RESEARCH GRANTS I have a continuous track record of peer-reviewed and industry funding since 2005. The most recent successes include one active NIH R01 grant, a fundable NIH R01 application and an additional R01 in review and two future R01s to be submitted in the next 12 months. My grant statistics are: AWARDED $9.7m from 16 awarded grants since 06/2005

Under review $5m NIH / NIAID, RFA-AI-17-026

RESEARCH TRAINING and MENTORING

Since 2006, I have trained, advised and mentored 30 students and postdocs. PhD students Co-advisor: 8 (including 5 completed) MSc mentor: 2 Postdocs: 4 Visiting scientists: 5 Research assistants: 3 Research intern students: 8

8 | P a g e

# Years Student Main / Co-advisor Main Objective

1 2018 - ongoing Ms. Rachel Poole M Summer intern student UF

2 2018 - ongoing Ms. Rachel Helgemoe M Intern student UF

3 2018 Mr. Jonathan Beutel Co Research technician UF

4 2018 Ms. Maria Peacock Co Research technician UF

5 2017 - ongoing Ms. Madeleine Behr Co OPS student Mines Univ. Golden, CO

6 2017 - ongoing Mr. Benedikt Huck Co Summer intern student UF

7 2017 - ongoing Mr. Nils Krumm Co Summer intern student UF

8 2017 - ongoing Mr. Alex Duarte Co Research intern student (BSc) UCF

9 2017 - ongoing Ms. Kristen Prince Co PharmD research student UF

10 2016 - ongoing Mr. Yuli Qian Co PhD student UF

11 2016 - ongoing Mr. Xun Tao Co PhD student UF

12 2016 - ongoing Mr. Brandon Klee Co PharmD research student UF

13 2016 - ongoing Ms. Priscell Villegas Co PharmD research student UF

14 2016 - ongoing Ms. Lijie Zhang Co Research technician UF

15 2013 - 2015 Mr. Gabriel Cabot Co/M PhD Student UIB, Palma de Mallorca, Spain

16 2013 - 2015 Mr.Jane Castillo - Vera Co Visiting Scientist, Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.

17 2014 - ongoing Mr. Gabriel Torrens Co PhD student UIB, Palma de Mallorca, Spain

18 2013 - 2014 Ms. Immaculada Nebot M Mentoring Master’s Thesis (MSc) UIB, Palma de Mallorca, Spain

19 2013 - 2014 Dr. Alaa Ropy M Visiting Scientist (BSc) Fayoum University, Al Fayyūm, Egypt

20 2013 - ongoing Ms. Isabel M. Barcelo M Mentoring Degree Final Project (BSc) & Master’s Thesis (MSc) UIB, Palma de Mallorca, Spain

21 2012 - 2015 Dr. Laura Zamorano Co/M PhD Student UIB, Palma de Mallorca, Spain

22 2012 - 2013 Dr. Alejandro Beceiro M Visiting Scientist, UDC A coruna, Spain

23 2012 - 2013 Ms. Anna k. Bystedt Co/M Research intern student (BSc) Linköpings

universitet, Linköping, Sweden

24 2011 (12-wk) Dr. Alicia Fajardo Co/M Visiting Scientist UAM, Madrid, Spain

25 2009 - 2010 Dr. Elena Lopez Co/M Research intern student (BSc) UAM, Madrid, Spain

9 | P a g e

EDITORIAL BOARD MEMBER

Frontiers in Microbiology, Frontiers Editorial Office, Lausanne, Switzerland (3rd most cited journal in Microbiology; #18 of 97 journals in Microbiology according to Eigenfactor® score, Impact factor: 4.076).

SCIENTIFIC ADVISOR TO EDITORS (SAE)

Journal of Pharmaceutical Sciences JPharmSci®, Elsevier on behalf of the American Pharmacists Association (United States), Washington, DC (#24 of 255 journals in Pharmacology & Pharmacy according to Eigenfactor® score, Impact factor: 2.855).

JOURNAL REVIEWER (ad hoc)

2018

2018

2018

2018

2018

2018

2017

2013

Reviewer, European Journal of Pharmaceutical Sciences

Reviewer, Microbial Drug Resistance

Reviewer, Antimicrobial Agents and Chemotherapy

Reviewer, Infection and Drug Resistance

Reviewer, Journal of Microbiological Methods

Reviewer, Antimicrobial Agents and Chemotherapy

Reviewer, European Journal of Pharmaceutical Sciences

Reviewer, PLoS One

2011 Reviewer, Journal of Infectious Diseases and Therapy

2009 Reviewer, Antimicrobial Agents and Chemotherapy

MEMBERSHIPS

ASM American Society for Microbiology, since 2008. ESCMID European Society of Clinical Microbiology and Infectious Diseases, since 2008. SEIMC Spanish Society Infectious Diseases and Clinical Microbiology, since 2005. REIPI Cooperative Network: Red Española de Investigación en Patología Infecciosa ID: RD/0015/006, Since 2005.

PUBLICATIONS

Publication summary Peer-reviewed papers: 34 published since 2005 h-index: 23 (total) 20 (since 2013)

10 | P a g e

i10-index: 28 26 (since 2013) Citations: >17000 (based on ISI Web of Knowledge, Scopus and Google Scholar) Note: Publications include high impact leading journals in the field of antimicrobial pharmacology and molecular biology such as mBio (IF: 6.87), PLoS Pathogens (IF: 8.98), JAC (IF: 4.55) and AAC (IF: 4.53) Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/sites/myncbi/1vKqBqwckzek7/bibliography/52592605/public/?sort=date&direction=ascending Peer-reviewed full papers: 1. Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP,

Shin BS, Drusano GL, Sörgel F, Landersdorfer CB. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clin Pharmacokinet. 2018 Jun 23. doi: 10.1007/s40262-018-0678-x. [Epub ahead of print]

2. Sutaria DS, Moya B, Green KB, Kim TH, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB. First penicillin-binding protein occupancy patterns of β-lactams and β-lactamase inhibitors in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018. PMID: 29712652

3. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrob Agents Chemother. 2017; 61: 01238-17. PMID: 28848013

4. Torrens G, Pérez-Gallego M, Moya B, Munar-Bestard M, Zamorano L, Cabot G, Blázquez J, Ayala JA, Oliver A, Juan C. Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS One. 2017; 12:e0181932. PMID: 28742861

5. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver A. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrobial Agents and Chemotherapy. 2017; 61:02529-16. PMID: 28289035.

6. Pérez-Gallego M, Torrens G, Castillo-Vera J, Moya B, Zamorano L, Cabot G, Hultenby K, Albertí S, Mellroth P, Henriques-Normark B, Normark S, Oliver A, Juan C. Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway? mBio. 2016; 7:01783-16. PMID: 27795406.

7. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L, Juan C, Tubau F, Rodríguez C, Moya B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A. Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy. 2016; 60:7415-7423. PMID: 27736752

8. Rojo-Molinero E, Macià MD, Rubio R, Moya B, Cabot G, López-Causapé C, Pérez JL, Cantón R, Oliver A. Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy. 2016; 60:2912-22. PMID: 26926631

9. Cabot G, Zamorano L, Moya B, Juan C, Navas A, Blázquez J, Oliver A. Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy. 2016; 60:1767-78. PMID: 26729493

10. Ropy A, Cabot G, Sánchez-Diener I, Aguilera C, Moya B, Ayala JA, Oliver A. Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance,

11 | P a g e

and peptidoglycan structure. Antimicrobial Agents and Chemotherapy. 2015; 59:3925-34. PMID: 25896695

11. Zamorano L, Moya B, Juan C, Mulet X, Blázquez J, Oliver A. The Pseudomonas aeruginosa CreBC two-component system plays a major role in the response to β-lactams, fitness, biofilm growth, and global regulation. Antimicrobial Agents and Chemotherapy. 2014; 58:5084-95. PMID: 24936599

12. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moya B, Juan C, Haussler S, Oliver A. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrobial Agents and Chemotherapy. 2014; 58:3091-9. PMID: 24637685

13. Martínez-Ramos I, Mulet X, Moya B, Barbier M, Oliver A, Albertí S. Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing. Antimicrobial Agents and Chemotherapy. 2014; 58:2426-9. PMID: 24419345

14. Mulet X, Cabot G, Ocampo-Sosa AA, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moya B, Peña C, Martínez-Martínez L, Oliver A. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrobial Agents and Chemotherapy. 2013; 57:5527-35. PMID: 23979744

15. López-Causapé C, Rojo-Molinero E, Mulet X, Cabot G, Moya B, Figuerola J, Togores B, Pérez JL, Oliver A. Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PloS one. 2013; 8:e71001. PMID: 23951065

16. Cabot G, Ocampo-Sosa AA, Domínguez MA, Gago JF, Juan C, Tubau F, Rodríguez C, Moya B, Peña C, Martínez-Martínez L, Oliver A. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrobial Agents and Chemotherapy. 2012; 56:6349-57. PMID: 23045355

17. Moya B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrobial Agents and Chemotherapy. 2012; 56:4771-8. PMID: 22733064

18. Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L, Suárez C, Peña C, Domínguez MA, Moncalián G, Oliver A, Martínez-Martínez L. Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study. Antimicrobial Agents and Chemotherapy. 2012; 56:1703-13. PMID: 22290967

19. Mulet X, Moya B, Juan C, Macià MD, Pérez JL, Blázquez J, Oliver A. Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrobial Agents and Chemotherapy. 2011; 55:4560-8. PMID: 21807976

20. Zamorano L, Reeve TM, Juan C, Moya B, Cabot G, Vocadlo DJ, Mark BL, Oliver A. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains. Antimicrobial Agents and Chemotherapy. 2011; 55:1990-6. PMID: 21357303

21. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial Agents and Chemotherapy. 2011; 55:1906-11. PMID: 21357294

22. Zamorano L, Reeve TM, Deng L, Juan C, Moya B, Cabot G, Vocadlo DJ, Mark BL, Oliver A. NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2010; 54:3557-63. PMID: 20566764

23. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2010; 54:3933-7. PMID: 20547785

12 | P a g e

24. Zamorano L, Moya B, Juan C, Oliver A. Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. The Journal of antimicrobial chemotherapy. 2010; 65:1540-2. PMID: 20435778

25. Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrobial Agents and Chemotherapy. 2010; 54:1213-7. PMID: 20086158

26. Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M, Ariza J. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. Journal of clinical microbiology. 2009; 47:2381-7. PMID: 19494059

27. Oteo J, Diestra K, Juan C, Bautista V, Novais A, Pérez-Vázquez M, Moya B, Miró E, Coque TM, Oliver A, Cantón R, Navarro F, Campos J. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International journal of antimicrobial agents. 2009; 34:173-6. PMID: 19464856

28. Moya B, Dötsch A, Juan C, Blázquez J, Zamorano L, Haussler S, Oliver A. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS pathogens. 2009; 5:e1000353. PMID: 19325877

29. Diestra K, Juan C, Curiao T, Moya B, Miró E, Oteo J, Coque TM, Pérez-Vázquez M, Campos J, Cantón R, Oliver A, Navarro F. Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. The Journal of antimicrobial chemotherapy. 2009; 63:60-6. PMID: 18988679

30. Diestra K, Coque TM, Miró E, Oteo J, Nicolau CJ, Campos J, Moya B, Curiao T, Pérez-Vázquez M, Cantón R, Oliver A, Navarro F. [Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella pneumoniae in 11 Spanish hospitals (2004)]. Enfermedades infecciosas y microbiologia clinica. 2008; 26:404-10. PMID: 18842234

31. Moya B, Juan C, Albertí S, Pérez JL, Oliver A. Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2008; 52:3694-700. PMID: 18644952

32. Plasencia V, Borrell N, Maciá MD, Moya B, Pérez JL, Oliver A. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrobial Agents and Chemotherapy. 2007; 51:2574-81. PMID: 17470655

33. Mena A, Maciá MD, Borrell N, Moya B, de Francisco T, Pérez JL, Oliver A. Inactivation of the mismatch repair system in Pseudomonas aeruginosa attenuates virulence but favors persistence of oropharyngeal colonization in cystic fibrosis mice. Journal of bacteriology. 2007; 189:3665-8. PMID: 17307847

34. Juan C, Moya B, Pérez JL, Oliver A. Stepwise upregulation of the Pseudomonas aeruginosa

chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three AmpD homologues. Antimicrobial Agents and Chemotherapy. 2006; 50:1780-7. PMID: 16641450

ORAL/POSTER PRESENTATIONS

1. Bulitta JB, Tao X, Kim TH, Moya B, Sutaria DS, Jiao Y, Zhou J, Beutel JA, Green KB, Barth A, Zavascki AP. Targeting polymyxin- and carbapenem-resistant Klebsiella pneumoniae (KPC-KP) via a novel, integrated mechanistic approach. ASM/ESCMID 2018, Lisbon, Portugal; Sep 4-7, 2018.

2. Sutaria DS, Moya B, Nierychlewski K, Shan J, Boyce JD, Jiao Y, Tao X, Bonomo RA, Velkov T, Louie A, Drusano G, Bulitta JB. Comprehensive Penicillin-Binding Protein (PBP) Occupancy Patterns of 18 Drugs in Acinetobacter baumannii. ASM/ESCMID 2018, Lisbon, Portugal; Sep 4-7, 2018.

13 | P a g e

3. Moya B, Shan J, Zhang L, Sutaria DS, Boyce J, Basso KB, Bonomo RA, Landersdorfer CB, Velkov T, Bulitta JB. First whole-cell assay to study the time-course of β-lactams inactivating Penicillin-Binding Proteins and first comprehensive PBP binding data in Acinetobacter baumannii. Gordon Research Conference on New Antibacterial Discovery & Development, Ventura, CA, USA; March 11-16, 2018.

4. Zhang L, Kim TH, Prince K, Dedaj N, Moya B, Tao X, Qian Y, Jiao Y, Sutaria DS, Bulitta JB. Extensive, synergistic killing of polymyxin-resistant Klebsiella pneumoniae carbapenemases producing Klebsiella pneumoniae by beta-lactam plus amikacin combinations. Gordon Research Conference on New Antibacterial Discovery & Development, Ventura, CA, USA; March 11-16, 2018.

5. Sutaria DS, Moya B, Green KB, Zhang L, Kim TH, Qian Y, Tao X, Jiao Y, Louie A, Drusano GL, Bulitta JB. Klebsiella pneumoniae – first Penicillin-Binding Protein occupancy patterns of β-lactams in this ‘superbug.’ Gordon Research Conference on New Antibacterial Discovery & Development, Ventura, CA, USA; March 11-16, 2018.

6. Tao X, Kim TH, Qian Y, Moya B, Zhang L, Jiao Y, Sutaria DS, Louie A, Bonomo RA, Drusano GL, Bulitta JB. Quantifying outer membrane permeability of five beta-lactams in Klebsiella pneumoniae carbapenemase producing K. pneumoniae via a novel cassette assay. Gordon Research Conference on New Antibacterial Discovery & Development, Ventura, CA, USA; March 11-16, 2018.

7. Sutaria DS, Moya B, Green KB, Jiao Y, Tao X, Louie A, Drusano GL, Bulitta JB. First comprehensive beta-lactam binding data to penicillin-binding proteins in Klebsiella pneumoniae. ASM Microbe 2018, Atlanta, GA, USA; June 7-11, 2018. (Submitted)

8. Tao X, Kim TH, Moya B, Jiao Y, Sutaria DS, Bonomo R, Bulitta JB. Simultaneous characterization of the outer membrane permeability in the presence and absence of Polymyxin B in Klebsiella pneumoniae carbapenemase producing K. pneumoniae. ASM Microbe 2018, Atlanta, GA, USA; June 7-11, 2018. (Submitted)

9. Bulitta JB, Shan J, Moya B, Sutaria DS, Boyce JD, Bonomo RA, Landersdorfer CB, Velkov T. First comprehensive Penicillin-binding protein occupancy patterns of beta-lactams in Acinetobacter baumannii. Abstract: 8477. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain; April 21-24, 2018.

10. Zhang L, Kim TH, Prince K, Dedaj N, Moya B, Tao X, Qian Y, Jiao Y, Sutaria DS, Barth A, Zavascki AP, Louie A, Drusano GL, Bulitta JB. Extensive, synergistic killing of polymyxin-resistant Klebsiella pneumoniae carbapenemase producing Klebsiella pneumoniae by β-lactam plus amikacin combinations. Abstract: 8450. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain; April 22, 2018. (Oral presentation)

11. Tao X, Kim TH, Qian Y, Moya B, Zhang L, Jiao Y, Sutaria DS, Bonomo RA, Barth A, Zavascki AP, Drusano GL, Louie A, Bulitta J. Novel cassette assay to simultaneously characterize the outer membrane permeability of five beta-lactams in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Abstract: 8462. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain; April 21-24, 2018.

12. Qian Y, Moya B, Zhang L, Tao X, Kim TH, Jiao Y, Sutaria DS, Bulitta JB. Imipenem kills Pseudomonas aeruginosa substantially faster than meropenem and doripenem most likely due to more rapid outer-membrane penetration. Abstract: 8432. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain; April 21-24, 2018.

13. Sutaria DS, Moya B, Zhang L, Kim TH, Qian Y, Tao X, Jiao Y, Louie A, Drusano G, Bulitta J. First data on Penicillin-binding protein occupancy patterns of beta-lactams in Klebsiella pneumoniae. Abstract: 8364. 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain; April 21-24, 2018.

14. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Oliver A. Unraveling the cefepime-zidebactam synergy basis against metallo-betalactamase (MBL)-producing Pseudomonas aeruginosa through penicillin-binding protein (PBP) binding dynamics. Oral Presentation 3953. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria; April 22-25, 2017

15. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Oliver A. Zidebactam (WCK 5107) and WCK 5153:

Bicyclo‐acyl hydrazide penicillin‐binding‐protein (PBP) inhibitors showing potent beta‐lactam

14 | P a g e

enhancer activity against multidrug‐resistant (MDR) metallo‐beta‐lactamase (MBL)‐producing Klebsiella pneumoniae. Poster: P4006 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria; April 22-25, 2017.

16. Moya B, Jiao Y, Qian Y, Tao X, Louie A, Bulitta JB. Inactivation of penicillin-binding protein 2 is critical for killing Pseudomonas aeruginosa at high but not at low bacterial density. Poster: P0237. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria; April 22-25, 2017.

17. Jiao Y, Moya B, Y Qian, X Tao, JB Bulitta. Equivalent efficacy and better safety of double beta-lactam vs. beta-lactam plus aminoglycoside combinations for Gram-negative infections – a systematic review of 12 randomized clinical trials. Poster EP0427. 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria; April 22-25, 2017.

18. Moya B, Barcelo IM, A. Udaykar A, Bhagwat S, Patel M, Bou G, Oliver A. WCK 5222 [Cefepime-Zidebactam, FEP-ZID]: Mechanistic Basis Behind Novel β-lactam–β-lactam Enhancer Combination Against Metallo-β-lactamase (MBL)-producing E. coli (EC) K. pneumoniae (KP), P. aeruginosa (PA) and its Impact on Therapeutically Relevant Bactericidal Exposures Assessed Through in vitro Pharmacodynamic Modelling (IVPM) and Mouse Lung Eradication Studies. Poster: 1982. IDWeek, New Orleans, LA; October 26-30, 2016.

19. Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Oliver A. WCK 5107 (Zidebactam) and WCK 5153: Bicyclo-acyl Hydrazide PBP2 Inhibitors Showing Potent β-lactam Enhancer Activity Against Acinetobacter baumannii, Including Multidrug-resistant (MDR) Carbapenemase-producing Clinical Strains. Poster: PLB42. 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands; April 9-12, 2016.

20. Cabot G, Macia MD, Tubau F, Moya B, Zamorano L, Juan C, Suarez C, Pena C, Martinez-Martinez L, Oliver A. Activity of CXA-101 Against a Large Collection of P. aeruginosa Blood Stream Isolates Overexpressing AmpC and the Major Efflux Pumps. Poster: XX-2209. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA; September 9-12, 2012

21. Moya B, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A. Pan-Beta-lactam resistance development in P. aeruginosa clinical strains: molecular mechanisms, PBPs profiles and binding affinities. Poster: C1 -169. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL; September 17-20, 2011

22. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Activity of CXA-101 against Pseudomonas aeruginosa ß-lactam Resistance Mechanisms: ampD, ampDh2, ampDh3, dacB (PBP4), and oprD Mutations. Poster: F1-1989. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA; September 12-15, 2009

23. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. Affinity of the New Cephalosporin CXA-101 (CXA) to Penicillin-Binding Proteins (PBPs) of Pseudomonas aeruginosa. Poster: F1-1985. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA; September 12-15, 2009

24. Moya B, Juan C, Blazquez J, Zamorano L, Perez JL, Oliver A. The CreBCD system is involved in one-step high level β-lactam resistance development in Pseudomonas aeruginosa. Oral Presentation C1-3729. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington D. C.; October 25-28, 2008